Authors

  • Bobokha L.Y., Makhmudova D.T., Aslonov M.N.
  • Aslonova Z.A.

Keywords:

SARS-CoV-2, COVID-19, ocular manifestations, conjunctivitis, ACE2, TMPRSS2, retinal microangiopathy.

References

Bakhshandeh B, Sorboni SG, Javanmard AR, Mottaghi SS, Mehrabi MR, Sorouri F, et al. Variants in ACE2; potential influences on virus infection and COVID-19 severity. Infect Genet Evol. (2021) 90:104773. doi: 10.1016/j.meegid.2021.104773

Belser JA, Rota PA, Tumpey TM. Ocular tropism of respiratory viruses. Curr Opin Ophthalmol. 2013;24(5):504–509. doi:10.1097/ICU.0b013e328363c3e4

Bosello F, Manganotti P, Calistri V, et al. Anti-MOG optic neuritis after SARS-CoV-2 infection. Mult Scler Relat Disord. 2021; 49:102763. doi: 10.1016/j.msard.2021.102763

Brann DH, Tsukahara T, Weinreb C, Lipovsek M, Van den Berge K, Gong B, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv. (2020) 6(31): eabc5801. doi: 10.1126/ sciadv.abc5801

Chen L, Deng C, Chen X, et al. Ocular manifestations of COVID-19. Graefes Arch Clin Exp Ophthalmol. 2020;258(8):1653–1661. doi:10.1007/s00417-020-04724-9

Collin J, Queen R, Zerti D, et al. Co-expression of SARS-CoV-2 entry genes in ocular tissues. Exp Eye Res. 2021; 205:108491. doi: 10.1016/j.exer.2021.108491

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. (2020) 181(2):271–280.e8. doi: 10.1016/j.cell.2020.02.052

Jun ISY, Anderson DE, Kang AEZ, et al. Viral shedding in tears in COVID-19. Ocul Immunol Inflamm. 2021;29(2):242–247. doi:10.1080/09273948.2020.1850393

Katopodis P, Kerslake R, Davies J, Randeva HS, Chatha K, Hall M, et al. COVID-19 and SARS-CoV-2 host cell entry mediators: Expression profiling of TMRSS4 in health and disease. Int J Mol Med. (2021) 47(4):64. doi: 10.3892/ijmm.2021.4897

Kaufman SC. Ocular surface immunity. Eye Contact Lens. 2021 ;47(2) :75–83. doi :10. 1097/ICL.0000000000000729

Loffredo L, Pacella F, Pacella E, et al. Conjunctivitis and COVID-19: a meta-analysis. J Clin Med. 2020;9(10):3026. doi:10.3390/jcm9103026

Marinho PM, Marcos AAA, Romano AC, et al. Retinal findings in patients with COVID-19. Lancet. 2020;395(10237):1610. doi:10.1016/S0140-6736(20)31014-X

Meduri A, Oliverio GW, Mancuso G, et al. Ocular surface manifestations of COVID-19. Eye (Lond). 2020;34(12):2109–2110. doi:10.1038/s41433-020-1031-0

Mohammed I, Subramanian A, Gupta N, et al. Dry eye disease following COVID-19. Clin Ophthalmol. 2022; 16:1761–1768. doi:10.2147/OPTH.S349199

Napoli PE, Nioi M. Global spread of COVID-19 and ophthalmology. Eye (Lond). 2020;34(7):1207–1208. doi:10.1038/s41433-020-0869-5

Otaif W, Al Somali AI, Al Habash A, et al. Episcleritis in COVID-19. Am J Ophthalmol Case Rep. 2020; 20:100917. doi: 10.1016/j.ajoc.2020.100917

Pirraglia MP, Ceccanti M, Cerini C, et al. Ischemic optic neuropathy in COVID-19. J Neuroophthalmol. 2020;40(4):491–494. doi:10.1097/WNO.0000000000001032

Pirraglia MP, Ceccanti M, Cerini C, et al. Optic nerve involvement in COVID-19. Front Neurol. 2021; 12:653433. doi:10.3389/fneur.2021.653433

Seah I, Agrawal R. Can the coronavirus disease 2019 (COVID-19) affect the eyes? Ocul Immunol Inflamm. 2020;28(3):391–395. doi:10.1080/09273948.2020.1738501

Senanayake P, Drazba J, Shadrach K, et al. Angiotensin II and its receptor subtypes in the human retina. Invest Ophthalmol Vis Sci. 2007;48(7):3301–3311. doi:10.1167/iovs.06-1024

Sheth JU, Narayanan R, Goyal J, et al. Retinal vein occlusion in COVID-19. Indian J Ophthalmol. 2020;68(11):2531–2534. doi: 10.4103/ijo.IJO_2380_20

Starr TN, Greaney AJ, Hilton SK, et al. SARS-CoV-2 RBD and ACE2 binding. Cell. 2020;182(5):1295–1310.e20. doi: 10.1016/j.cell.2020.08.012

Turker AK, Kaya S, Koc M. Steroid-induced glaucoma after COVID-19. Ocul Immunol Inflamm. 2022;30(5):1163–1167. doi:10.1080/09273948.2021.1965190

Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection in COVID-19. Lancet. 2020;395(10234):1417–1418. doi:10.1016/S0140-6736(20)30937-5

Vavvas DG, Sarraf D, Sadda SR, et al. OCTA retinal changes in COVID-19. Sci Rep. 2021;11:683. doi:10.1038/s41598-020-79961-7

Vavvas DG, Sarraf D, Sadda SR, et al. Retinal findings in COVID-19. Br J Ophthalmol. 2020;104(9):1185–1186. doi:10.1136/bjophthalmol-2020-316220

World Health Organization. data.who.int, WHO Coronavirus (COVID-19) dashboard > More resources [Dashboard]. (2023). Available online at: https://data.who.int/dashboards/ covid19/more-resources.

Wu P, Duan F, Luo C, et al. Characteristics of ocular findings of patients with COVID-19. JAMA Ophthalmol. 2020;138(5):575–578. doi:10.1001/jamaophthalmol.2020.1291

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. (2020) 323(13):1239–42. doi: 10.1001/jama.2020.2648

Xia J, Tong J, Liu M, et al. Evaluation of coronavirus in tears and conjunctival secretions. J Med Virol. 2020;92(6):589–594. doi:10.1002/jmv.25725

Zhou L, Xu Z, Castiglione GM, et al. ACE2 and TMPRSS2 expression on the ocular surface. J Med Virol. 2020;92(8):1352–1360. doi:10.1002/jmv.25885